Literature DB >> 25633118

Treating COPD in Older and Oldest Old Patients.

Andrea Corsonello, Simone Scarlata, Claudio Pedone, Silvia Bustacchini, Sergio Fusco, Anna Zito, Raffaele Antonelli Incalzi1.   

Abstract

The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting betaagonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe airflow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Nonpharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and agerelated changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.

Entities:  

Mesh:

Year:  2015        PMID: 25633118     DOI: 10.2174/1381612821666150130121229

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs.

Authors:  Hiroto Tokumoto; Hiroyuki Tominaga; Yoshiya Arishima; Go Jokoji; Masaki Akimoto; Hideo Ohtsubo; Eiji Taketomi; Nobuhiko Sunahara; Satoshi Nagano; Yasuhiro Ishidou; Setsuro Komiya; Takao Setoguchi
Journal:  Nutrients       Date:  2018-02-18       Impact factor: 5.717

2.  When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.

Authors:  S Gaduzo; V McGovern; J Roberts; J E Scullion; D Singh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-13

3.  The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study.

Authors:  Raffaele Antonelli Incalzi; Giorgio Walter Canonica; Nicola Scichilone; Sara Rizzoli; Lucia Simoni; Francesco Blasi
Journal:  PLoS One       Date:  2019-09-13       Impact factor: 3.240

4.  Association between Geriatric Nutrition Risk Index and Skeletal Muscle Mass Index with Bone Mineral Density in Post-Menopausal Women Who Have Undergone Total Thyroidectomy.

Authors:  Tai-Hua Chiu; Szu-Chia Chen; Hui-Chen Yu; Jui-Sheng Hsu; Ming-Chen Shih; He-Jiun Jiang; Wei-Hao Hsu; Mei-Yueh Lee
Journal:  Nutrients       Date:  2020-06-05       Impact factor: 5.717

5.  Association between the Geriatric Nutritional Risk Index, bone mineral density and osteoporosis in type 2 diabetes patients.

Authors:  Liang Wang; Die Zhang; Jing Xu
Journal:  J Diabetes Investig       Date:  2020-01-20       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.